Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib with VXLD chemotherapy for childhood relapsed/refractory ALL and LLy
NCT03817320Phase 2Active, not recruiting
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Feb 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ixazomib in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Started Feb 2019; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03817320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817320.